BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $389
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Evan Seigerman has maintained an Outperform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $385 to $389.
August 04, 2023 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has maintained an Outperform rating on Vertex Pharmaceuticals and raised the price target from $385 to $389.
The Outperform rating maintained by BMO Capital indicates a positive outlook for Vertex Pharmaceuticals. The increase in price target from $385 to $389 suggests that the analyst expects the stock to perform well in the short term. This could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100